10 Best Peptides for Fat Loss (Ranked by Results) | Newtropin

If you’re exploring peptide therapy for fat loss, the good news is that science has identified a growing list of peptides that can meaningfully accelerate body recomposition — often working through mechanisms that diet and exercise alone can’t replicate. The best peptides for fat loss target specific hormonal pathways: some boost growth hormone secretion, others suppress appetite, and some directly break down stored adipose tissue. This guide ranks ten of the most effective peptides for fat loss by their clinical evidence and real-world results, and shows you how stacking certain peptides can amplify your outcomes dramatically.

Fat-Loss Peptides by Evidence

This page ranks single peptides. Of the ten, only semaglutide and tirzepatide have large randomized trials showing clinically meaningful weight loss, and tesamorelin has randomized-trial evidence for visceral fat specifically; the rest rely mainly on animal or small human studies.

PCAC votes are advisory; see the FDA Peptide Status Tracker for current status.

Best Peptides for Weight Loss vs Fat Loss

"Weight loss" and "fat loss" are often used interchangeably, but the evidence splits along that line. If the goal is the best peptides for weight loss measured on the scale, the GLP-1-class drugs are in a category of their own: in STEP 1, semaglutide produced a mean 14.9% reduction in body weight at 68 weeks versus 2.4% with placebo, and in SURMOUNT-1, tirzepatide produced mean reductions of 15–21% across dose arms at 72 weeks versus 3.1% with placebo. Both are FDA-approved prescription drugs rather than research peptides, and semaglutide also reduced major cardiovascular events in the SELECT trial.

Some of that weight is lean mass, not fat. GH-axis peptides are studied for the opposite profile: shifting body composition toward less fat, especially visceral fat, with little change in total weight. Tesamorelin is the only one with randomized-trial support for that effect, and those trials enrolled people with HIV-associated abdominal fat. For CJC-1295, ipamorelin, sermorelin, AOD-9604 and HGH Fragment 176–191, fat-loss claims rest mostly on mechanism and animal data. For compounded versus brand-name GLP-1 access, see GLP-1 medications: compounded vs. commercial options.

1. CJC-1295 + Ipamorelin

Often considered the gold standard of peptide-based fat loss, CJC-1295 (a growth hormone-releasing hormone analogue) and Ipamorelin (a ghrelin mimetic and GHRP) work synergistically to produce sustained, pulsatile growth hormone release. CJC-1295 extends the half-life of GHRH signaling while Ipamorelin amplifies the GH pulse without causing cortisol or prolactin spikes. Elevated GH levels directly stimulate lipolysis — the breakdown of fat stored in adipocytes — and improve insulin sensitivity, making this stack highly effective for visceral fat reduction. Controlled human data on how quickly body composition changes are limited. See our CJC-1295 + Ipamorelin page for full dosing protocols and expected outcomes.

2. Semaglutide

Semaglutide is a GLP-1 receptor agonist that has taken the medical weight loss world by storm, with clinical trials showing average fat loss of 15–20% of body weight over 68 weeks. It works primarily by reducing appetite, slowing gastric emptying, and increasing satiety signals in the hypothalamus. While technically a peptide drug (it’s a 31-amino-acid molecule), it is FDA-approved for chronic weight management as Wegovy and for type 2 diabetes as Ozempic. Its powerful appetite suppression makes it one of the most impactful tools for rapid fat loss, particularly for patients with metabolic syndrome or insulin resistance. It’s most effective when combined with lifestyle changes and sometimes stacked with metabolism-boosting peptides like Tesamorelin.

3. Tesamorelin

Tesamorelin is an FDA-approved GHRH analogue originally developed for HIV-associated lipodystrophy, but it has gained traction in the anti-aging and body recomposition space for its potent ability to reduce visceral adipose tissue (VAT). Clinical data shows reductions in VAT of up to 18% after 26 weeks of use. Tesamorelin works by stimulating the pituitary to release GH in a physiological, pulsatile manner, which then activates IGF-1 and drives lipolysis preferentially in visceral fat depots. It’s particularly valuable for patients with central adiposity driven by age-related GH decline. Its FDA approval gives it additional credibility as a pharmaceutical-grade fat loss intervention.

4. HGH Fragment 176–191

HGH Fragment 176–191 is a truncated peptide derived from the C-terminal end of human growth hormone — specifically the portion responsible for fat metabolism. Unlike full HGH, the fragment does not affect insulin sensitivity or IGF-1 levels, making it a highly targeted fat-burning compound with a cleaner side effect profile. Preclinical research suggests it mimics GH’s lipolytic activity without GH’s proliferative effects; controlled human evidence is limited. It’s especially well-suited for users who want localized or generalized fat reduction without the water retention sometimes associated with full GH therapy. Often stacked with CJC-1295 for synergistic GH pathway activation.

5. AOD-9604

AOD-9604 (Anti-Obesity Drug 9604) is another HGH fragment — specifically residues 177–191 with a modified tyrosine residue — that was originally developed by Metabolic Pharmaceuticals as an obesity treatment. It has demonstrated anti-obesity effects in both animal models and human trials, working by stimulating lipolysis and inhibiting lipogenesis (the formation of new fat) without the glucose-raising effects of full HGH. Studies suggest it regulates fat metabolism through beta-3 adrenergic receptors. In human clinical trials, AOD-9604 showed statistically significant fat loss versus placebo at higher doses. It’s often used in stacks with GHRP-6 for appetite modulation and enhanced GH release.

6. Tirzepatide

Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist, representing the next generation beyond semaglutide. Clinical trials (SURMOUNT-1) demonstrated average weight loss of ~22.5% of body weight at the highest dose — making it arguably the most powerful approved fat loss agent ever studied. Like semaglutide, it’s a therapeutic peptide that reduces appetite and improves metabolic function, but its additional action on GIP receptors enhances insulin secretion and appears to improve fat cell metabolism. Tirzepatide is available by prescription as Mounjaro and Zepbound. With the FDA shortage resolved, compounding copies of the approved drug is restricted — see compounded tirzepatide in 2026. The tirzepatide dosage chart covers the labeled titration schedule.

7. MOTS-c

MOTS-c is a mitochondria-derived peptide encoded within mitochondrial DNA — making it unique among the peptides on this list. It activates AMPK (AMP-activated protein kinase), the cellular energy sensor, which promotes fat oxidation, improves insulin sensitivity, and enhances metabolic flexibility. Animal studies show MOTS-c can reduce diet-induced obesity and reverse insulin resistance, and early human research is promising. It essentially signals cells to switch from glucose to fat as a fuel source, improving metabolic efficiency in a way that complements other GH-based peptides. MOTS-c levels naturally decline with age, making it particularly interesting for older adults with metabolic slowdown.

8. BPC-157

Body Protective Compound 157 (BPC-157) is derived from a protein found in human gastric juice. While not primarily a fat loss peptide, it earns a place on this list through its powerful anti-inflammatory and gut-healing effects, which have secondary metabolic benefits. Gut inflammation and dysbiosis are increasingly recognized as drivers of obesity and metabolic dysfunction. BPC-157 modulates the gut-brain axis, reduces systemic inflammation, and supports nitric oxide signaling — all of which can improve insulin sensitivity and create a metabolic environment more conducive to fat loss. It’s most often stacked with other fat loss peptides as a supportive foundation. See our CJC-1295 + Ipamorelin page for how BPC-157 fits into a stacking protocol.

9. Sermorelin

Sermorelin is a synthetic analogue of GHRH (growth hormone-releasing hormone), specifically the first 29 amino acids of the 44-amino-acid GHRH peptide — the biologically active portion. It was the first GHRH analogue approved by the FDA (for pediatric GH deficiency) and remains a popular, well-studied option for adult HGH restoration. By stimulating the pituitary to release GH naturally, Sermorelin supports lipolysis, lean muscle preservation, and improved body composition. It’s considered one of the safer, more beginner-friendly peptides for fat loss, with a relatively low side effect profile. It doesn’t suppress natural GH production, which gives it a distinct advantage over exogenous HGH for long-term use.

10. TB-500

TB-500 (Thymosin Beta-4) is a wound-healing and recovery peptide that supports fat loss indirectly through its pro-anabolic and anti-inflammatory properties. By accelerating muscle repair and reducing recovery time, TB-500 allows users to train harder and more frequently — which is ultimately one of the most sustainable drivers of fat loss. It also promotes the growth of new blood vessels (angiogenesis) and reduces fibrotic tissue, helping the body function more efficiently during recomposition. While not a direct fat-burning compound, TB-500 is a powerful complement to GH-secreting peptides in any serious body recomposition stack.

Ready to Find the Right Peptide Protocol for Fat Loss?

The most effective fat loss peptide approach is rarely a single compound — it’s a thoughtfully designed stack tailored to your metabolic profile, goals, and health history. Whether you’re interested in starting with the classic CJC-1295 + Ipamorelin combo or exploring more advanced protocols with semaglutide or Tesamorelin, the first step is working with a qualified provider. Providers can start at For Providers to connect with Newtropin’s licensed 503A compounding partner. Newtropin does not prescribe, compound, or dispense.

Medical Disclaimer This content is for informational purposes only. Always consult a qualified healthcare provider before starting any peptide or hormone therapy.

Single Peptides vs Stacks

This guide ranks peptides one at a time, because that is how the evidence exists: trials test single agents, not combinations. In practice, clinicians sometimes combine a GH-axis peptide with a recovery or appetite-focused compound. If you are comparing combinations rather than individual compounds, our guide to peptide stack combinations for recomposition covers five common pairings, what each component adds and the evidence behind them.

Frequently Asked Questions

What is the best peptide for weight loss?

Tirzepatide and semaglutide have the strongest evidence, with mean weight reductions of roughly 15–21% in phase 3 trials. Both are FDA-approved prescription drugs, and the choice between them is a clinical decision based on the patient's history, tolerance and access.

What peptide burns the most belly fat?

Tesamorelin is the only peptide with randomized-trial evidence for reducing visceral (abdominal) fat specifically, and it is FDA-approved as Egrifta for HIV-associated abdominal fat. GLP-1 drugs also reduce visceral fat as part of overall weight loss.

Is semaglutide a peptide?

Yes. Semaglutide is a modified 31-amino-acid peptide analogue of human GLP-1, and tirzepatide is also a peptide. Unlike most research peptides, both are FDA-approved drugs with large outcome trials.

Do growth hormone peptides cause weight loss?

GH-axis peptides such as CJC-1295, ipamorelin and sermorelin raise GH and IGF-1, which promotes fat breakdown, but there are no large randomized trials showing meaningful weight loss with them. Their effect, where studied, is on body composition rather than scale weight. See our guide to growth hormone peptides for fat loss for more.

Are fat-loss peptides legal?

FDA-approved peptide drugs are legal by prescription. Most other fat-loss peptides are not FDA-approved and not on the 503A Bulks List; July 2026 PCAC votes in favor of MOTS-c, BPC-157 and TB-500 are advisory until FDA completes rulemaking. Check the FDA Peptide Status Tracker for current status.

Weight-Loss Peptide Guides

This page is the starting point for Newtropin's weight-loss peptide content. The guides below go deeper on each compound and question.

Where Compounding Stands in 2026

Compounded access has changed since this ranking was first written. Compounding of semaglutide and tirzepatide was widespread during the documented shortages, under shortage-related FDA guidance. The shortages have ended, so compounding essentially-copies of Mounjaro, Zepbound, or Wegovy is restricted unless the prescriber documents a clinically significant difference for that specific patient. See compounded tirzepatide in 2026. Retatrutide and cagrilintide are investigational, and neither has an established 503A pathway (see retatrutide through compounding pharmacies). For peptides reviewed by the FDA's compounding committee, check the FDA peptide status tracker. Newtropin does not prescribe, compound, or dispense. We connect licensed providers with a licensed 503A compounding partner.

GLP-1 and Incretin Drugs

• Semaglutide: the GLP-1 receptor agonist behind Ozempic and Wegovy
• Tirzepatide: the dual GIP/GLP-1 agonist behind Mounjaro and Zepbound
• Tirzepatide dosage chart: the labeled titration schedule, step by step
• Microdosing tirzepatide: what low-dose use means and what the evidence shows
• Compounded tirzepatide in 2026: sourcing, legality and patient counseling
• Retatrutide: the investigational triple GLP-1/GIP/glucagon agonist
• Retatrutide dosage: the doses studied in clinical trials, and why there is no label
• Retatrutide side effects: what trials have reported so far
• Retatrutide vs tirzepatide vs semaglutide: receptor profiles and trial results compared
• Cagrilintide: the investigational amylin analogue studied with semaglutide

Other Weight-Management Compounds

• AOD-9604: the HGH fragment studied for lipolysis
• 5-Amino-1MQ: an NNMT inhibitor studied in adipocyte metabolism
• Tesofensine: a monoamine reuptake inhibitor studied for appetite
• Emerging weight-loss peptides: newer compounds in development
• Growth hormone peptides for fat loss: CJC-1295, ipamorelin, tesamorelin and AOD-9604

Safety

• Weight-loss peptide safety guide: side effects, monitoring and medical supervision

References

1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PubMed
3. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. PubMed
4. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PubMed
5. Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PubMed
6. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed
7. Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. PubMed
8. Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PubMed
9. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PubMed
10. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. PubMed